Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 15;1(4):230-236.
doi: 10.1016/j.adro.2016.07.002. eCollection 2016 Oct-Dec.

Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial

Akihiro Ohba  1 , Ken Kato  1 , Yoshinori Ito  2 , Chikatoshi Katada  3 , Hiromichi Ishiyama  4 , Sachiko Yamamoto  5 , Takashi Ura  6 , Takeshi Kodaira  7 , Shigehiro Kudo  8 , Yoshio Tamaki  8
Affiliations

Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial

Akihiro Ohba et al. Adv Radiat Oncol. .

Abstract

Purpose: The most effective treatments in elderly patients with esophageal cancer remain a subject of debate. This multicenter phase 2 study was designed to evaluate the efficacy and toxicity of chemoradiation therapy (CRT) with docetaxel (DTX) in elderly patients with stage II/III (non-T4) esophageal cancer.

Methods and materials: Patients ≥70 years of age with clinical stage II/III esophageal cancer received DTX at a weekly dose of 10 mg/m2 during 6 consecutive weeks and concurrent radiation therapy (60 Gy in 30 fractions). The primary endpoint was the 2-year survival rate, and the required number of enrolled patients was 37.

Results: Between July 2008 and January 2011, 16 patients were enrolled. The study was prematurely closed because of slow accrual. Characteristics of the patients were as follows: median age, 77 years (range, 73-81); performance status 0/1, 4/12; and clinical stage IIA/IIB/III, 3/4/9. Of the 16 patients, 14 (87.5%) completed the CRT. The 2-year survival rate was 62.5% (90% confidence interval [CI], 42.5-82.5). The median survival time was 27.7 months (95% CI, 23.3-32.2 months) and the median progression-free survival was 15.2 months (95% CI, 5.4-25.0 months). Seven patients achieved complete response, resulting in a complete response rate of 43.8% (95% CI, 19.8-70.1). Grade 3 or higher acute toxicities included esophagitis (31.3%), anorexia (12.5%), leukopenia (6.3%), neutropenia (6.3%), thrombocytopenia (6.3%), mucositis (6.3%), and infection (6.3%). Grade 3 or higher late toxicities included esophagitis (12.5%), pleural effusion (12.5%), pneumonitis (6.3%), and pericardial effusion (6.3%).

Conclusions: CRT with DTX might be a treatment option for elderly patients with stage II/III esophageal cancer, particularly for patients who are medically unfit for surgery or cisplatin-containing therapy. However, further improvements of this therapy are required to decrease the incidence of esophagitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Overall survival and (B) progression-free survival.
See this image and copyright information in PMC

References

    1. Parkin D.M., Bray F., Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2007 Foundation for Promotion of Cancer Research.
    1. Bonavina L., Incarbone R., Saino G. Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. Dis Esophagus. 2003;16:90–93. - PubMed
    1. Steyerberg E.W., Neville B., Weeks J.C. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: A population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389–2396. - PubMed
    1. Kinugasa S., Tachibana M., Yoshimura H. Esophageal resection in elderly esophageal carcinoma patients: Improvement in postoperative complications. Ann Thorac Surg. 2001;71:414–418. - PubMed

LinkOut - more resources